TS-003701 — This IP is a notable departure from conventional clinical research practices and introduces a new model that brings the research directly to individuals’ homes. The approach eliminates logistical challenges and potential disruptions associated with traditional on-site research visits. Certified staff ensure study compliance, maintaining the integrity of data collection and study protocols. By facilitating research participation from the comfort of home, the technology enhances participant recruitment and retention rates. It mitigates the occurrence of missed study visits and biological sample collections, streamlining the research process and improving overall study completion rates. These benefits not only expedite the research timeline but also contribute to more accurate and reliable research outcomes. The paradigm shift towards personalized and convenient clinical trial participation is the IP’s standout feature. By eliminating the need for frequent travel to research sites, Clinical Research Delivered addresses a longstanding challenge in clinical research. This approach not only augments the efficiency and effectiveness of research endeavors; it also fosters a more participant-centric model, ultimately enhancing the value proposition for both study sponsors and participants.

TS-000859 — Nephrotic syndrome (NS) is a common kidney disease found in children that creates an overabundance of protein in the urine, comparable to proteinuria in adults. As of now, there are no approved safe and effective treatment for NS, especially for those whose NS is steroid or multi-drug resistant. A team of researchers have identified a series of new molecular targets for future drug development. Using glomerular transcriptomes and informatic analysis, clinicians will be able to identify immunosuppressive approaches that are distinct from the current procedures.

TS-000737 — Nephrotic syndrome (NS) is a common kidney disease found in children that creates an overabundance of protein in the urine, comparable to proteinuria in adults. As of now, there are no approved safe and effective treatment for NS, especially for those whom NS is steroid or multi-drug resistant. Current treatments for NS are only partially effective and often create notable toxicity, but existing thiazolidinediones (TZDs) used for proteinuria in adults have resulted in reduction of proteins found in the urine. Introducing the TZD pioglitazone (PIO) to a trial study conducted by Dr. William Smoyer, pediatric patients with multi-drug resistant NS showed notable proteinuria reduction in comparable time periods, both before and after the addition of PIO in their medical regimens.